Immune Response to Influenza Vaccine in Islet Cell Transplant Recipients

University of Alberta61 enrolled

Overview

Influenza virus is an important cause of morbidity in the transplant population and can lead to viral and bacterial pneumonia. Although the annual influenza vaccine is recommended for organ transplant patients, studies have shown that the standard inactivated influenza vaccine has poor immunogenicity in this population. The investigators plan to test the humoral response to vaccination and look at HLA upregulation

OBJECTIVE AND HYPOTHESIS * To test the specific humoral response of the influenza vaccine after islet cell transplantation * To test the production of HLA alloantibodies after vaccination.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Transplant

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult islet cell transplant recipients * Able to provide informed consent Exclusion Criteria: * Egg allergy * Previous life-threatening reaction to influenza vaccine (ie Guillain Barre Syndrome) * Febrile illness in the past two weeks * Unable to provide informed consent

Locations (1)

University of Alberta Hospital

Edmonton, Alberta, Canada

Outcomes

Primary Outcomes

•Seroprotection rate

defined as a post-vaccination titer of ≥1:40

Time frame: 3 months

Secondary Outcomes

•Seroconversion rate

defined as a 4-fold increase in titer from pre- to post-vaccination.

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.